Member Info for Candid

diamond drilling results are expected so buyers are building positions ahead of this news.
No guarantees of course but that’s the nature of exploration.

I remember Verona Pharma popped over 120% higher when it did it’s oversubscribed $200m placing in July, I wonder how SNG will react...

Absorbing the selling by BGF very well, considering such a small amount of shares are in issue.

“we initiate our coverage on Argo with an in- depth report on its investment case in due course.”

Haven’t seen the report yet but will share it once it’s available.

Just read the RNS again and it points to a potential gold core target at depth. The results to-date are only up-to 350m depth, so it looks like the market is getting excited about the results to be announced in the coming weeks for 350-700m (4 holes pending). The way the RNS is worded does seem to indicate that a higher gold core is likely, the big question is what size this could be..

European approval should be a given as AMYT already have AP101 EU approval for partial thickness wounds, similarly FDA accelerated approval should also come in time, so CVR holders will see a nice bonus.
Will be interesting to see what US pharma industry makes of this as it’s the 1st EB treatment that has passed stage III trials. I would expect the BOD to fend off any bids at this stage as the company is way too undervalued to consider a buyout.

Great news today and am really glad AMYT has a positive outcome after such a long phase III trial.
FDA approval should be almost a certainty now, especially with a clean safety record

I agree, the August trend should continue the post lockdown recovery along with more details from the various regions. The balance sheet should be looking a lot more healthy following the repayment of the c.£45 million in cash, that’s pretty significant.
Share price is ticking up today which usually is a good sign..

47m @ 0.3g/t is nothing to write home about but remember this is just the 1st hole from the 6 being drilled.
I think they need to go deeper to really find what’s there. Will be very interesting to see BLP040 at depth of 600m+ As per the photo in the RNS. Mention of drilling to 750m suggests there is good potential deeper.
Remember that GGP’s huge gold discovery at Haveiron is at depths of 600-900m.

The political aspect is probably less of a risk than touted. The current coalition government is fragmented and weak, it is not functioning properly and it will eventually be toppled, probably quite soon. Spain has had 4 general elections in 4 years and likely to be a 5th one sooner rather than later.

Welcome news today on the grant and potential covid treatment, this isn’t even DEST’s lead asset so a nice bonus if it comes good.
Shares are very tightly held, over 70% of which directors hold approx 20%. Won’t take much for this to run to 100p +

Those two 200k trades are likely sells judging by the time of the transactions and the price at the time.
Explains the fall in the shareprice. Question is, if this is a one-off or the emergence of a seller with more to come.

With the Rights Issue launching next week on 8th Sept, what are thoughts on entitlement and pricing?

Interesting to see further stakes from US funds, I believe that’s the 3rd US fund who has built a stake.
It might be a home for some of the Acacia shares after their selling spree, they also had 2.14% remaining on 21st July

Thanks BermudaShorts, yes I remember that trial now, it was a few years ago and indeed Amicus did provide all the data to Amryt. This trial was analysed and published recently in a journal, with conclusions about the trial design, so I do hope Amryt have taken similar advice in their trial design.
“These observations are of considerable interest and may help inform the study design of future trials in patients with EB, which may benefit from a vehicle run-in phase to exclude patients who respond to vehicle controls or improved wound care.”

Guidance upgraded. Recovery is looking good

The Amicus phase III trial for EB (also a topical cream) recently published failed results due to a better than expected placebo response, a vehicle cream in this case:
“Results showed that SD-101 failed to show statistically significant improvement in wound healing compared to the vehicle cream. Likewise, no benefits were found in pain or itching.
An analysis found a higher-than-expected placebo response rate in patients given the control cream, which increased over time. Researchers then suggested that lanolin oil and cod liver oil, which were components of the vehicle cream and have known skin healing properties, could have driven the unexpected effects”

My questions are, why would they use a placebo cream with ingredients that have known skin healing properties?!
Am I correct in stating that the placebo cream in the case of Amryt’s AP101 is pure sunflower oil?

Looking at the chart, a close above 90p will be very positive here and push on to £1 +

With top-line data due within 5-6 weeks what are thoughts on the potential shareprice gain or loss?
I’ll guessing a 50-70% gain on a successful readout and 30-40% drop on a failed readout.
However could rerate to considerably more over time with an FDA approval.

Trump is turning up the heat on FDA to get the approvals process moving faster:

“In a tweet on Saturday, President Trump said "the deep state, or whoever, at the FDA is making it very difficult for drug companies to get people in order to test the vaccines and therapeutics.
Earlier this year, US regulators gave emergency authorisation to Gilead Science Inc's remdesivir as a therapeutic treatment for coronavirus.
Meanwhile, a report by the Financial Times suggests the White House is considering granting emergency authorisation for a vaccine being developed by Oxford University and pharmaceutical giant AstraZeneca, ahead of the US presidential election on 3 November.”